Coupled Plasma Filtration Adsorption in Patients with a History of Kidney Transplantation: Report of Two Cases.
Coupled plasma filtration adsorption (CPFA) is an extracorporeal treatment based on plasma filtration associated with an adsorbent cartridge and hemofiltration. CPFA is able to remove inflammatory mediators and it has been used to treat severe sepsis, septic shock and multiple organ dysfunction syndrome. Limited experience exists on the use of CPFA after solid organ transplantation. We report our experience with CPFA in 2 kidney transplant recipients with post-nephrolithotomy septic shock and severe unexplained rhabdomyolysis. In both the cases, excellent results were observed. In selected cases, CPFA can be safely and effectively used in patients with a solid organ transplant. However, additional studies are needed in this particular setting, to further investigate the potential role of CPFA for the treatment of other conditions associated with excessive inflammation, such as in rheumatologic disorders and delayed graft function.
Transplant Unit, Department of Surgery, University of L'Aquila, San Salvatore Hospital, L'Aquila, Italy.
Quirino
Q
Lai
Verdiana
V
Di Pietro
Samuele
S
Iesari
Sofia
S
Amabili
Linda
L
De Luca
Katia
K
Clemente
Antonio
A
Famulari
Francesco
F
Pisani
D000368:Aged; D002116:Calcitonin / Q000097:blood; D005260:Female; D006440:Hemofiltration / Q000295:instrumentation / Q000379:methods*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000473:pathology / Q000601:surgery; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009211:Myoglobin / Q000097:blood; D009403:Nephrostomy, Percutaneous / Q000009:adverse effects*; D011498:Protein Precursors / Q000097:blood; D012206:Rhabdomyolysis / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D012772:Shock, Septic / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D016896:Treatment Outcome
D009211:Myoglobin; D011498:Protein Precursors; D002116:Calcitonin